Cyclodextrin-Based Arsenal for Anti-Cancer Treatments

Crit Rev Ther Drug Carrier Syst. 2023;40(2):1-41. doi: 10.1615/CritRevTherDrugCarrierSyst.2022038398.

Abstract

Anti-cancer drugs are mostly limited in their use due to poor physicochemical and biopharmaceutical properties. Their lower solubility is the most common hurdle limiting their use upto their potential. In the recent years, the cyclodextrin (CD) complexation have emerged as existing approach to overcome the problem of poor solubility. CD-based nano-technological approaches are safe, stable and showed well in vivo tolerance and greater payload for encapsulation of hydrophobic drugs for the targeted delivery. They are generally chosen due to their ability to get self-assembled to form liposomes, nanoparticles, micelles and nano-sponges etc. This review paper describes a birds-eye view of the various CD-based nano-technological approaches applied for the delivery of anti-cancer moieties to the desired target such as CD based liposomes, niosomes, niosoponges, micelles, nanoparticles, monoclonal antibody, magnetic nanoparticles, small interfering RNA, nanorods, miscellaneous formulation of anti-cancer drugs containing CD. Moreover, the author also summarizes the various shortcomings of such a system and their way ahead.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents*
  • Cyclodextrins* / chemistry
  • Humans
  • Liposomes
  • Micelles
  • Nanoparticles* / chemistry
  • Solubility

Substances

  • Cyclodextrins
  • Liposomes
  • Micelles
  • Antineoplastic Agents